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ALP is further downregulated, but Runx2 is upregulated. Endothelial cell marker genes, such as CD31
and CD34, are upregulated with 50 µg/mL aCaP and a 2-week exposure. Inter-donor variability is high:
Two out of three donors show a significant upregulation of ALP and Runx2 at day 14 with 50 µg/mL aCaP
compared to 5 µg/mL aCaP. Notably, all changes in stem cell commitment are obtained in the absence of
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Simple Summary: Calcium phosphate is an important component in natural bone. Bone defects
caused by trauma or resection of tumors demand bone substitutes to close the defect. One viable
option is to use a scaffold material seeded with stem cells. Stem cells can differentiate towards bone
cells (osteoblasts), among other cell types. To trigger stem cells towards the osteoblast type of cell,
particular supplementation of the culture medium is needed. This study tests whether calcium
phosphate nanoparticles can induce a commitment towards the osteoblast type of cell. In addition,
we test for other commitments, such as endothelial cell, chondrocyte, or adipocyte commitment.
After 1 or 2 weeks, with either 5 or 50 µg/mL nanoparticles in the culture medium, gene expression
is analyzed. We find a significant increase of two specific bone marker genes after two weeks in
50 µg/mL nanoparticles compared to 5 µg/mL for two out of three tested human donors of adipose-
derived stem cells. Moreover, endothelial cell commitment is also induced. Hence, such nanoparticles
have the potential to trigger osteogenic and endothelial cell commitment.
Abstract: Amorphous calcium phosphate (aCaP) nanoparticles may trigger the osteogenic commit-
ment of adipose-derived stem cells (ASCs) in vitro. The ASCs of three human donors are investigated
using basal culture medium DMEM to either 5 or 50 µg/mL aCaP nanoparticles suspension (control:
no nanoparticles). After 7 or 14 days, stem cell marker genes, as well as endothelial, osteogenic, chon-
drogenic, and adipogenic genes, are analyzed by qPCR. Free calcium and phosphate ion concentra-
tions are assessed in the cell culture supernatant. After one week and 5 µg/mL aCaP, downregulation
of osteogenic markers ALP and Runx2 is found, and averaged across the three donors. Our results
show that after two weeks, ALP is further downregulated, but Runx2 is upregulated. Endothelial
cell marker genes, such as CD31 and CD34, are upregulated with 50 µg/mL aCaP and a 2-week
exposure. Inter-donor variability is high: Two out of three donors show a significant upregulation of
ALP and Runx2 at day 14 with 50 µg/mL aCaP compared to 5 µg/mL aCaP. Notably, all changes
in stem cell commitment are obtained in the absence of an osteogenic medium. While the chemical
composition of the culture medium and the saturation status towards calcium phosphate phases
remain approximately the same for all conditions, gene expression of ASCs changes considerably.
Hence, aCaP nanoparticles show the potential to trigger osteogenic and endothelial commitment
in ASCs.
Keywords: amorphous calcium phosphate; nanoparticle; adipose-derived stem cells; osteogenesis;
angiogenesis; chondrogenesis; adipogenesis; hydroxyapatite; calcium ion; phosphate ion
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1. Introduction
Calcium phosphate (Ca3(PO4)2) is a biomaterial that is often used in orthopedic
surgery, either in the form of cement [1,2], ceramic [3], or coating of titanium implants [4].
Nanoparticles of calcium phosphate may originate from mechanical abrasion of implant
materials, as well as through degradation of larger entities. Nanoscopic calcium phosphate
has been reported to represent no health risk to the human body because calcium phosphate
nanoparticles are easily resorbed and dissolved by macrophages [5].
Calcium phosphate nanoparticles have been chemically produced by wet- and dry-
based methods, such as precipitation or flame spray pyrolysis [6]. Furthermore, calcium
phosphate phases differ in terms of solubility, where crystalline forms like alpha-tricalcium
phosphate (α-TCP) and beta-tricalcium phosphate (β-TCP) are less soluble in aqueous
solution than amorphous tricalcium phosphate (aCaP) [7], resulting in higher free calcium
(Ca2+) and phosphate ion (Pi) concentrations in equilibrium with solid aCaP. Amorphous
calcium phosphate has gained a lot of attention, due to its bioactivity; it easily transforms
to hydroxyapatite (HAp) [8], the main inorganic component of natural bone [9]. Like
this, aCaP is an interesting material for bone tissue engineering purposes, particularly if
combined with an organic phase to give nanocomposites, such as PLGA/aCaP [10–12].
During the last two decades, adipose tissue-derived mesenchymal stem cells (ASCs)
have been proven attractive for cellular therapy and bone tissue engineering purposes,
because they are easily harvested and available in quite high amounts compared to other
sources [13–16]. Their tri-lineage differentiation potential makes them sensitive towards
corresponding culture medium supplementation, with osteogenesis, chondrogenesis, and
adipogenic differentiation belonging to the essential stem cell criteria defined by Dominici
et al. [17]. For in vitro osteogenic differentiation, a phosphate source should be supplied to
the medium to enable the alkaline phosphatase (ALP) of ASCs to produce Pi ions which
take part in mineralization and the formation of HAp. Usually, β-glycerophosphate is
used for this purpose; however, critical comments about its high and non-physiological
concentration (10 mM), as well as the wide fluctuations of the Pi ions during differenti-
ation experiments, have been raised [18]. Therefore, other phosphate sources have been
suggested, such as sodium hydrogen phosphate buffer [18,19] or polyphosphate [20].
As various calcium phosphate-based biomaterials have shown to trigger osteogenesis
in ASCs even in the absence of osteogenic culture medium (i.e., without β-glycerophosphate
or other further phosphate sources) [21,22], the question arises if aCaP nanoparticles sus-
pended in basal culture medium Dubelcco’s Modified Eagle’s Medium (DMEM) [23] can
evoke an osteogenic commitment. The novelty of our approach lies in using amorphous
calcium phosphate nanoparticles, not crystalline nanoparticles; and in using very low
concentrations of suspended particles, such as 5 and 50 µg/mL, respectively. The addition
of a small number of aCaP nanoparticles to DMEM with a subsequent ultrasound step
to suspend them is easy to perform. The potential impact of such nanoparticles lies in
their prospective ability to trigger osteogenic commitment in stem cells, to provide a Pi
source, and to transform into HAp. Therefore, we exposed ASCs of three human donors
to aCaP nanoparticles in vitro and assessed the gene expression at 1 and 2 weeks for two
different concentrations; 5 and 50 µg/mL, respectively, where cell viability was guaranteed
in contrast to 500 µg/mL where ASCs had been shown to die due to chemical stress [10].
We hypothesized that:
(a) Gene expression of osteo-associated commitment would be enhanced with more
aCaP nanoparticles in DMEM in a dose-dependent manner, while gene expression of
endothelial cell commitment, chondrogenic and adipogenic commitment would be
reduced in the presence of such nanoparticles.
(b) Gene expression changes would be more prominent at two weeks compared to 1 week.
(c) Human ASCs of three donors would behave individually different from each other
with regard to gene expression changes—however, similar trends would occur.
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2. Materials and Methods
2.1. Synthesis of aCaP Nanoparticles
The aCaP nanoparticles (Ca/P = 1.5) were synthesized by flame spray pyrolysis
according to Loher et al. [24] using calcium-2-ethylhexanoic salt, which was synthesized
with calcium hydroxide (Riedel de Haen, Ph. Eur.) and ethylhexanoic (Sigma-Aldrich,
St. Louis, MO, USA) and tributyl phosphate (Sigma-Aldrich, 98%). Transmission electron
microscopy (TEM, FEI, Philips CM 12) was used to assess particle morphology and to




Figure 1. TEM image of the aCaP nanoparticles used in this study (A) and size distribution (B).
2.2. Cell Isolation
Human ASCs were isolated from adipose tissue with the informed consent of the
patient according to Swiss (Züricher Kantonale Ethik-Kommission KEK-ZH: StV 7-2009)
and international ethical guidelines (ClinicalTrials.gov Identifier: NCT01218945) as re-
ported earlier [25]. The extraction procedure was performed after Zuk et al. [13], and
approved by the Swiss ethical guidelines (KEK-ZH: StV 7-2009). ASCs were characterized
by established procedures [10,26]. Of the 30 isolated primary ASC lines [25], three donors
were randomly selected: Donor D1: female, 45 years, subabdominal fat; donor D2: male,
39 years, subabdominal fat; donor D3: female, 41 years, abdominal fat.
2.3. Multilineage Cell Differentiation
Lineage-specific differentiation of ASCs towards the osteoblast, the adipogenic, the
endothelial, and the chondrogenic cell lineage had been achieved previously [27], using
cell culture media supplementation [13]. Osteogenic differentiation was evaluated by Von
Kossa and Alizarin red staining, CD31 immunohistochemical staining was used to see
the endothelial cell differentiation, and Alcian Blue staining to verify chondrogenesis. To
visualize the adipogenic differentiation, Oil Red O staining was performed. For the primary
ASCs used in this study, these four in vitro differentiations had been tested and performed
before, and used according to induction media. The results were presented earlier [27,28].
2.4. ASC Cultivation with aCaP Nanoparticles
For the aCaP experiments and the controls, 200,000 of human ASCs of three donors
(biological replicates n = 3) were cultivated in 6-well plates using 2 mL DMEM medium
with 10% FBS and 50 µg mL−1 gentamycine for 1 or 2 weeks in a humidified atmosphere of
95% air and 5% CO2 at 37
◦C. The medium was changed every 3 or 4 days, where the aCaP
nanoparticles were replaced with every medium change. Passages used for the experiments
were P5 (D1), P3 (D2), and P7 (D3). As for the medium spiked with aCaP nanoparticles, a
suspension of 3 mg/mL aCaP nanoparticles in pure H2O was prepared and sonicated for
10 min in an ultrasound bath to get a final concentration of 5 µg/mL or 50 µg/mL aCaP;
the stock solution was diluted with complete cell culture medium. Aliquots of 3 mL were
taken from this suspension and added to the ASCs. Cells that were cultivated without
nanoparticles served as a negative control. Furthermore, cells that were cultivated in an
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osteogenic induction medium served as a positive control. Induction medium consisted
of DMEM with 10% FBS, 50 µg mL−1 gentamycine, 10 mM β-glycerophosphate, 50 µM
ascorbic-2-phosphate and 100 nM dexamethasone. At the end of the experiments at 1
or 2 weeks, respectively, cells were collected for qPCR. The sample size was n = 3 (three
experiments per donor), and technical replicates for qPCR were also n = 3.
2.5. Quantitative Real Time PCR
Total RNA was extracted from the ASCs using RNeasy Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions. The RNA was quantified using
Nanodrop ND-1000 Spectrophotometer (Witec, Sursee, Switzerland), and 250 ng RNA was
reversed transcribed into cDNA using oligo-dT primers (Invitrogen), dNTP mix (Invitrogen,
Waltham, MA, USA), DTT (Invitrogen), 5x FSB (Invitrogen), RNA inhibitor (Applied
Biosystem, Waltham, MA, USA), and Superscript III reverse transcriptase (Invitrogen).
Quantitative PCR was performed using the SYBR® Green master mix (Applied Biosystems),
as well as primers synthesized by Microsynth (Balgach, Switzerland). For primer sequences,
see Table S1.
Primers for mesenchymal stem cells CD73, CD90 and CD105, for CD31 and CD34
(markers of endothelial cells) [29], for Runx2 and ALP (early osteogenesis), for collagen I
(medium osteogenesis) and osteocalcin (late osteogenesis), for PPAR-γ-2 (key transcription
factor during adipogenesis) [30], and Sox9 (key transcription factor for chondrogenesis) [31]
were used.
2.6. Measurement of Free Calcium and Phosphate Ion Concentrations
The calcium ions in the cell culture supernatant were determined by photometric
analysis. Calcium ions and o-cresolphthalein form a chromogenic complex in which the
calcium ion concentration is proportional to the measured absorbance at 575 nm. For this,
the Calcium Colometric Assay Kit (Sigma-Aldrich) was used and performed according to
the manufacturer’s instructions. All samples and standards were run in duplicates, and
50 µL samples were added per well. For the quantitative assessment of the phosphate
ions in the supernatant, no pretreatment was required. The phosphate concentration was
evaluated based on the color intensity measured at 620 nm, since malachite green dye and
molybdate, together with inorganic phosphate, form a stable complex. Samples of 50 µL of
the cell culture supernatant were analyzed with the QuantiChrom Phosphate Assay Kit
(BioAssay Systems, Hayward, CA, USA) and according to the manufacturer’s instructions.
2.7. Statistics
The data were analyzed with StatView 5.0.1 software. One-way statistical analysis of
variance (ANOVA) was conducted to test the significance of differences between different
concentrations of aCaP nanoparticles and control. Unpaired t-tests were performed to
compare time points, 7 and 14 days of incubation, respectively. Two-way ANOVA was
conducted to test significant differences in phosphate and calcium ion concentrations,
respectively, with levels of time and concentration. Pairwise comparison probabilities (p)
were calculated using the Fisher’s PLSD post hoc test to evaluate differences between the
groups. p values < 0.05 were considered significant (denoted as *); for p < 0.01 ** and for
p < 0.001 ***. Values were expressed as means ± standard deviations.
3. Results
3.1. Impact of aCaP Nanoparticles on Gene Expression of Stem Cells
Gene expression of 11 target genes was assessed for two time points and for two
concentrations of aCaP nanoparticles. Figure 2 shows the average manifold expression from
three different donors compared to the basal culture medium without aCaP nanoparticles
(=no TCP, no tricalciumphosphate). Stem cell markers were mainly unaffected, with two
exceptions; one for CD73, where a significant upregulation was found for 50 µg/mL
aCaP at day 14 compared to control (no aCaP). Moreover, the second for CD90, where
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it experienced a downregulation, when 5 µg/mL aCaP at day 7 were compared with
the control.
Regarding the two endothelial cell markers, CD31 and CD34, respectively, gene
expression averaged over the three donors showed a significant increase if the value at day
14 with 50 µg/mL aCaP was compared to the control (no TCP). ALP as a representative early
osteogenic differentiation marker was downregulated at day 7 in a dose-dependent manner,
while Runx2 was downregulated at day 7 when 5 µg/mL aCaP were compared to the
control; however, it was upregulated when 50 µg/mL were compared to 5 µg/mL. Further
osteogenic marker genes, such as collagen I and osteocalcin, were not affected. Finally,
PPAR-γ-2, representing one important marker during adipogenesis, was upregulated
at day 14 for both 5 and 50 µg/mL aCaP, when compared to the control, while Sox 9
(important for chondrogenesis) was not affected.
To get more insight into the individual response of each donor and to show individual
comparisons at a glance (Figure 2A’–K’), we provide three tables (Tables 1–3). They denote
changes determined when 5 µg/mL aCaP were compared to control (Table 1), when
50 µg/mL aCaP were compared with 5 µg/mL aCaP (Table 2) and when expression at day
14 was compared to day 7 (Table 3). Further quantitative information can be found in the
Supplementary Figures S1–S6.
Figure 2. Cont.
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γ
Figure 2. Average manifold induction of different genes averaged for three human donors (A–K)
and corresponding nested plots for the three donors (D1, D2, and D2) with means and standard
deviations for each donor (A’–K’). Representative images for 0 aCaP (L) and 50 µg/mL aCaP (M)
after 14 days. Experiments were carried out for three conditions and two time points, with 0, 5,
or 50 µg/mL aCaP nanoparticles (TCP = aCaP nanoparticles) and induction for 7 or 14 days in
culture, respectively. Results are given as means, and error bars denote standard deviations. For gene
expression in osteogenic culture medium, see Appendix A, Figure A1.
Table 1. Changes in gene expression of ASCs from three Donors (D1–D3) in the presence of 5 µg/mL
aCaP nanoparticles suspended in basal medium DMEM compared to basal medium DMEM without
nanoparticles, after incubation of 7 days and 14 days, respectively. Detailed results are given in the
Supporting Information Figures S1–S3. Key: ↑ = upregulation; ↓ = downregulation; * = p < 0.05;
** = p < 0.01; *** = p < 0.001; - = no significant change in gene expression. For example, ↑ * means
upregulation at a significance level with p < 0.05.
D1 D2 D3 D1 D2 D3
from 0 to 5 µg/mL from 0 to 5 µg/mL
Day 7 Day 14
CD73 - - ↓ ** - - -
CD90 - - ↓ *** ↑ ** - -
CD105 - - - - - -
CD31 - - - - - -
CD34 ↑ * - - - - -
ALP - - - - ↓ * -
Runx2 ↓ ** - ↓ ** - - -
Collagen I - ↓ ** ↓ *** - ↓ * -
Osteocalcin - ↓ *** - - ↑ *** -
PPAR-γ-2 - ↓ *** ↓ * - - -
Sox9 - ↓ ** ↓ *** - - -
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Table 2. Changes in gene expression of ASCs from three Donors (D1–D3) in the presence of 50 µg/mL
aCaP. nanoparticles suspended in basal medium DMEM compared to 5 µg/mL aCaP nanoparticles
suspended in basal medium DMEM, after incubation of 7 days and 14 days, respectively. Detailed
results are given in the Figures S1–S3. Key: ↑ = upregulation; ↓ = downregulation; * = p < 0.05; ** = p
< 0.01; *** = p < 0.001; - = no significant change in gene expression.
D1 D2 D3 D1 D2 D3
from 5 to 50 µg/mL from 5 to 50 µg/mL
Day 7 Day 14
CD73 - - - ↑ ** - ↑ **
CD90 - - ↑ *** - - ↑ ***
CD105 - - - - ↑ *** ↑ ***
CD31 - - ↑ ** ↑ *** - ↑ ***
CD34 ↓ ** - - - - ↑ ***
ALP - - ↓ ** ↑ ** - ↑ ***
Runx2 ↑ *** - - - ↑ ** ↑ ***
Collagen I - - - - - -
Osteocalcin ↓ ** ↑ *** ↓ * - - ↑ ***
PPAR-γ-2 - ↑ ** - - - -
Sox9 - ↑ * ↑ ** - - -
Table 3. Changes in gene expression of ASCs from three Donors (D1–D3) at 2 weeks of incubation
compared to 1 week in the presence of 5 µg/mL aCaP nanoparticles suspended in basal medium
DMEM and 50 µg/mL aCaP nanoparticles suspended in basal medium DMEM, respectively. Detailed
results are given in the Figures S4–S6. Key: ↑ = upregulation; ↓= downregulation; * = p < 0.05; ** = p
< 0.01; ***= p < 0.001; - = no significant change in gene expression.
D1 D2 D3 D1 D2 D3
from 1 to 2 Weeks from 1 to 2 Weeks
at 5 µg/mL aCaP at 50 µg/mL a CaP
CD73 ↑ *** ↑ *** - - - ↑ **
CD90 - ↑ *** ↑ *** - - ↑ ***
CD105 - - - - ↑ * ↑ ***
CD31 - ↑ *** ↑ *** - - ↑ ***
CD34 ↑ *** - ↑ * - - ↑ ***
ALP ↑ ** - - - - ↑ **
Runx2 ↑ * - - ↓ ** - ↑ ***
Collagen I - - ↑ *** - - ↑ ***
Osteocalcin ↑ *** ↑ *** ↑ * ↑ *** - ↑ ***
PPAR-γ-2 - - ↑ *** - ↑ *** ↑ *
Sox9 - - ↑ ** ↑ * - ↑ ***
When screening the impact of 5 µg/mL aCaP nanoparticles suspended in basal culture
medium on the gene expression of three different hASC donors, we found that after an
incubation period of 1 week, several genes were significantly downregulated; in two out of
three donors, Runx2 and collagen I were downregulated, as well as PPAR-γ-2 and Sox9
(Table 1). When comparing 5 µg/mL aCaP with particle-free conditions (control) at two
weeks of incubation, two out of three donors showed no significant differences.
An increase of the aCaP nanoparticle concentration from 5 to 50 µg/mL suspended
in DMEM revealed a significant upregulation of Sox9 gene expression in two out of three
donors at 1 week of incubation, while osteocalcin experienced a downregulation. However,
at two weeks, Sox9 expression did not show any significant changes anymore (in all
three donors), while ALP and Runx2 revealed an upregulation in two out of three donors
(Table 2). Moreover, CD31 was significantly upregulated, as well as the stem cell markers
CD73 and CD105 (in two out of three donors) (Table 2).
An obvious result for comparing the gene expression at two weeks with the time
point at one week of incubation was a general upregulation of many genes considered here.
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Specifically, osteocalcin was significantly upregulated in all three donors for the 5 µg/mL
experiment and in two out of three donors for the 50 µg/mL experiment, although the
average of the three donors, gene expression was not showing any significance (Figure 2I).
In addition, both endothelial cell marker genes and the stem cell markers CD73 and CD90
were upregulated at 5 µg/mL aCaP. As for the 50 µg/mL aCaP experiment, besides the
osteocalcin also CD105, PPAR-γ-2, and Sox9 were significantly upregulated (Table 3).
Individual profiling, thus, reveals the biological diversity and the different sensitivity of
human ASCs, harvested from different donors, with respect to their changes in commitment
when exposed to aCaP nanoparticles.
3.2. Free Calcium and Phosphate Concentrations
Initially and at time points 7 and 14 days, the free Ca2+ ion concentration, as well as
the phosphate Pi concentrations, were assessed in the culture media. The analysis revealed
that calcium ion concentrations were higher than provided by the basal culture medium
DMEM, where a 1.8 mM concentration is given. As for the phosphate concentration, it was
lower compared to the concentration provided by DMEM, given with 0.9 mM (Figure 3).
Measured Ca2+ concentrations were slightly fluctuating over time, with the highest values
on day 7 for all three different concentrations of 0, 5, and 50 µg/mL aCaP, respectively
(Figure 2A). Measured phosphate concentrations remained quite stable over time, but
with different levels for each aCaP concentration. They were on average lowest for the
medium without aCaP, as well as for medium with 5 µg/mL aCaP; and highest for medium
with 50 µg/mL aCaP, respectively. The saturation status for all conditions was calculated
(Table 4).
− − − − − −
− − − −
− − − −
− − − −
− − − −
− − − −
− − − −
− − − −
− − − −
Figure 3. Average free calcium concentrations (A) and phosphate concentrations (B) for three
conditions and two three points, with 0, 5, or 50 µg/mL aCaP nanoparticles and initially, as well
as 7 or 14 days in culture, respectively. Two-way ANOVA for Ca2+ revealed significant differences
between day 0 and day 7 (p = 0.0003), day 7 and day 14 (p = 0.0001), 0 and 5 µg/mL aCaP (p = 0.0113,
marked with *), as well as 0 and 50 µg/mL aCaP (p = 0.0132, marked with *). Two-way ANOVA for
phosphate revealed significant differences between day 0 and day 7 (p = 0.0323), day 0 and day 14
(p = 0.0027), 0 and 5 µg/mL aCaP (p = 0.0300, marked with *), 0 and 50 µg/mL aCaP (p < 0.0001,
marked with ***), as well as 5 and 50 µg/mL aCaP (p = 0.0100, marked with **). Error bars indicate
standard deviations.
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Table 4. Ionic activity products (Qs0) and differences between logQs0-logKs0 for nine different conditions (numbered 1–9),
i.e., no aCaP, 5, or 50 µg/mL aCaP and time points 0, 7, and 14 days, respectively, calculated based on measured free calcium
and phosphate ion concentrations (see Figure 2). No corrections regarding ionic strength were made.
A
DAY 0 DAY 7 DAY 14
No aCaP [32] 1 1 2 2 3 3
Solubility







Phase Ks0 Qs0 logQs0-logKs0 Qs0 logQs0-logKs0 Qs0 logQs0-logKs0
Ca(H2PO4)2 H2O 0.072443596 1.014 × 10−9 −7.85 8.011 × 10−10 −7.96 7.282 × 10−10 −8.00
CaHPO4 2H2O 2.34423 × 10−7 1.540 × 10−6 0.82 1.384 × 10−6 0.77 1.278 × 10−6 0.74
CaHPO4 9.54993 × 10−8 1.540 × 10−6 1.21 1.384 × 10−6 1.16 1.278 × 10−6 1.13
Ca8(HPO4)2(PO4)4 5H2O 1.25893 × 10−96 7.285 × 10−41 55.76 4.029 × 10−41 55.51 2.187 × 10−41 55.24
alpha-Ca3(PO4)2 3.16228 × 10−26 5.543 × 10−15 11.24 4.585 × 10−15 11.16 3.660 × 10−15 11.06
beta-Ca3(PO4) 2 3.16228 × 10−30 5.543 × 10−15 15.24 4.585 × 10−15 15.16 3.660 × 10−15 15.06
Ca10-x(HPO4)x(PO4)6x(OH)2-x
(0<x<1) 7.94328 × 10
−86 1.703 × 10−43 42.33 9.640 × 10−44 42.08 4.902 × 10−44 41.79
Ca10(PO4)6(OH)2 6.3096 × 10−118 3.983 × 10−46 71.80 2.306 × 10−46 71.56 1.099 × 10−46 71.24
Ca4(PO4)2O 3.16228 × 10−40 1.296 × 10−17 22.61 1.097 × 10−17 22.54 8.205 × 10−18 22.41
B
DAY 0 DAY 7 DAY 14
5 uM aCaP [32] 4 4 5 5 6 6
Solubility







Phase Ks0 Qs0 logQs0-logKs0 Qs0 logQs0-logKs0 Qs0 logQs0-logKs0
Ca(H2PO4)2 H2O 0.072443596 1.091 × 10−9 −7.82 1.495 × 10−9 −7.69 1.199 × 10−9 −7.78
CaHPO4 2H2O 2.34423 × 10−7 1.539 × 10−6 0.82 2.140 × 10−6 0.96 1.679 × 10−6 0.86
CaHPO4 9.54993 × 10−8 1.539 × 10−6 1.21 2.140 × 10−6 1.35 1.679 × 10−6 1.25
Ca8(HPO4)2(PO4)4 5H2O 1.25893 × 10−96 6.255 × 10−41 55.70 9.013 × 10−40 56.85 1.240 × 10−40 55.99
alpha-Ca3(PO4)2 3.16228 × 10−26 5.140 × 10−15 11.21 1.403 × 10−14 11.65 6.632 × 10−15 11.32
beta-Ca3(PO4) 2 3.16228 × 10−30 5.140 × 10−15 15.21 1.403 × 10−14 15.65 6.632 × 10−15 15.32
Ca10-x(HPO4)x(PO4)6x(OH)2-x
(0<x<1) 7.94328 × 10
−86 1.358 × 10−43 42.23 2.761 × 10−42 43.54 2.917 × 10−43 42.56
Ca10(PO4)6(OH)2 6.3096 × 10−118 2.948 × 10−46 71.67 8.459 × 10−45 73.13 6.862 × 10−46 72.04
Ca4(PO4)2O 3.16228 × 10−40 1.116 × 10−17 22.55 4.298 × 10−17 23.13 1.560 × 10−17 22.69
C
DAY 0 DAY 7 DAY 14
50 uM aCaP [32] 7 7 8 8 9 9
Solubility







Phase Ks0 Qs0 logQs0-logKs0 Qs0 logQs0-logKs0 Qs0 logQs0-logKs0
Ca(H2PO4)2 H2O 0.072443596 2.707 × 10−9 −7.43 1.593 × 10−9 −7.66 1.094 × 10−9 −7.82
CaHPO4 2H2O 2.34423 × 10−7 2.638 × 10−6 1.05 2.075 × 10−6 0.95 1.584 × 10−6 0.83
CaHPO4 9.54993 × 10−8 2.638 × 10−6 1.44 2.075 × 10−6 1.34 1.584 × 10−6 1.22
Ca8(HPO4)2(PO4)4 5H2O 1.25893 × 10−96 2.224 × 10−39 57.25 5.848 × 10−40 56.67 8.306 × 10−41 55.82
alpha-Ca3(PO4)2 3.16228 × 10−26 1.788 × 10−14 11.75 1.165 × 10−14 11.57 5.754 × 10−15 11.26
beta-Ca3(PO4) 2 3.16228 × 10−30 1.788 × 10−14 15.75 1.165 × 10−14 15.57 5.754 × 10−15 15.26
Ca10-x(HPO4)x(PO4)6x(OH)2-x
(0<x<1) 7.94328 × 10
−86 5.715 × 10−42 43.86 1.582 × 10−42 43.30 1.905 × 10−43 42.38
Ca10(PO4)6(OH)2 6.3096 × 10−118 1.469 × 10−44 73.37 4.278 × 10−45 72.83 4.369 × 10−46 71.84
Ca4(PO4)2O 3.16228 × 10−40 4.595 × 10−17 23.16 3.151 × 10−17 23.00 1.320 × 10−17 22.62
4. Discussion
Large bone defects demand accurate bone substitutes that support the healing pro-
cess [33]. The gold standard in clinics is still using grafts from the iliac crest, sometimes
mixed with a bone substitute like Bio-Oss® [34]. However, such autologous bone grafts
may have disadvantages like donor site morbidity besides limited availability. In addition,
a second intervention is needed to provide the autologous graft for the defect. Finally,
patient comorbidities and the possibility of infection must be considered. Hence, tissue
engineering of bone grafts is one viable option to address those problems, arising from the
clinical treatment of critical size bone defects [35].
During the last decades, a lot of research has been performed in terms of bone tissue
engineering, where stem cells were used to support the regeneration and the formation of
new bone at the defect site [36–38]. Specifically, the differentiation of stem cells towards the
osteoblast phenotype has been under view [39]. Under laboratory conditions, the addition
of supplements to the basal cell culture medium has been established [13,40]. Reliable and
reproducible protocols for osteogenic differentiation have been determined and practiced.
Moreover, stage-specific expression of osteogenic marker genes have been defined [39],
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and the impact of several supplements, such as dexamethasone [41], ascorbic acid, or
β-glycerophosphate, on the osteogenic differentiation of stem cells have been tested [42].
Among the supplements for osteogenic differentiation, the external phosphate source
is a key parameter. It should be provided in addition to the phosphate in the culture




−, H3PO4 depending on the pH). While β-glycerophosphate
in a 10 mM concentration facilitates the mineralization of the extracellular matrix, other
phosphate sources, such as a buffer of sodium dihydrogen phosphate with disodium hy-
drogenphosphate [18] or polyphosphate [20], can be used. Moreover, besides the standard
osteogenic culture medium originally proposed by Zuk et al. [13], there are other osteogenic
induction media at hand, with additional vitamin D3 and/or BMP-2 [19] or a bioactive
glass component [43]. On the other hand, biomineralization demands calcium, where the
continuous remodeling of bone releases Ca2+ ions, which may unite with phosphate to
different calcium phosphate phases [32]. Among those phases, calcium-deficient hydrox-
yapatite (CDHAp) is very insoluble, with a pKs0 of 85 at 37
◦C [32], while amorphous
calcium phosphate is much better soluble. Notably, Ca2+ ions were reported to enhance
and support osteogenic differentiation [44,45].
In this study, we addressed the effects of amorphous calcium phosphate nanoparticles
suspended in basal culture medium DMEM without any further supplementation (no
β-glycerophosphate, no additional phosphate buffer, nor polyphosphate). For this purpose,
ASCs of three human donors were exposed to DMEM either with no aCaP nanoparticles
(control) or with 5 or 50 µg/mL for one and two weeks, respectively. In addition, ASCs
cultured in an osteogenic culture medium served as a positive control (Figure A1). As
for the donors, they were all aged between 39 and 45 years, and they were patients in the
Clinic for Plastic Surgery and Hand Surgery at the University Hospital Zurich, Switzerland,
during 2010 and 2011 (KEK-ZH: StV 7-2009).
Different rationales stand behind this approach. First, suspended nanoparticles may
trigger the osteogenic commitment without further supplementation as they provide a
calcium and phosphate source—without being toxic [5]. Like this, an easy tool would
be available for the change in stem cell commitment and for in vitro preparation of bone
constructs. Second, the inter-donor comparison might be of interest in the discussion of
individual sensitivity towards these nanoparticles. Third, calcium phosphate nanoparticles
are used as delivery systems for RNA [46], and our study might elucidate the effects of
the aCaP nanoparticles on the differentiation behavior of stem cells without RNA loading
(aCaP nanoparticles as mere vehicles).
Major findings were that the suspended aCaP nanoparticles enhanced gene expression
of CD73, CD31, CD34, and PPAR-γ-2 for the 50 µg/mL concentration and a 2-week expo-
sure, while they reduced gene expression of ALP and Runx2 for 5 µg/mL concentrations
and a 1-week exposure (Figure 2A–K). Importantly, these results were obtained from the
average gene expression of three human donors. A closer look at each individual donor,
however, showed a non-negligible inter-donor variability (Figure 2A’–K’), stressing the
need to consider individual cell responses towards such nanoparticle exposition. Finally,
we assessed the free calcium and phosphate ion concentrations and found a generally
increased calcium concentration compared with the theoretically given 1.8 mM (provided
by the culture medium), while the phosphate concentration was in most cases lower than
the theoretically 0.9 mM given by the medium.
The definition of minimal stem cell criteria by Dominici et al. includes the gene
expression of CD73, CD90, and CD105 [17]. In our study, we determined a significantly
increased expression of CD73 in the presence of 50 µg/mL aCaP nanoparticles after two
weeks of exposure, averaged for the three donors. Recently, an ALP+/CD73+ subpopulation
of human ASCs had been shown to exhibit an enhanced osteogenic potential compared
with unsorted ASCs in conventional osteogenic culture medium [28]. Moreover, CD73
knock-out mice were reported to have a delayed bone regeneration and also a reduced
bone matrix deposition. These findings were explained by CD73 as a key regulator of
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skeletal growth and an osteoblast activator. Thus, if osteogenic commitment is desired,
increased expression of CD73 can be judged as a positive effect on the ASC commitment.
Gene expression of typical endothelial cell marker CD31 was also significantly in-
creased in the presence of aCaP nanoparticles after a 2-week exposure, supported by
significantly higher CD34 gene expression [47]. It is well known that induced pluripotent
stem cells (iPSCs) [48], and ASCs are capable of endothelial cell differentiation, although
induction by endothelial cell differentiation medium EGM-2MV showed differences in
species, with rat ASCs differentiating more easily towards endothelial cells than human
ASCs [49]. During bone healing, angiogenesis is a crucial factor, and many bone tissue
engineering approaches; therefore, not only focus on the osteogenic potential, but also on
the angiogenic potential [50]. For example, this osteo/angiogenic potential was addressed
by a combination of poly lactic-co-glycolic acid incorporated with micro-nano bioactive
glass and mouse bone mesenchymal stem cells [51] or β-tricalcium phosphate seeded
with canine bone marrow mesenchymal stem cells [52]. Therefore, our findings of an
increase in endothelial cell marker gene expression are beneficial, even if it is only a slight
change in commitment towards the endothelial phenotype, most probably undergone in a
subpopulation of the otherwise heterogeneous ASC culture [28]. Interestingly, we found a
very similar and significant increase in CD31 and CD34 gene expression in conventional
osteogenic induction culture medium for a 2-week experiment (Figure A1), supporting the
usefulness of aCaP nanoparticles to act as an alternative for osteogenic supplementation.
Besides, the significant induction of CD34 gene expression in ASCs might also be attributed
to replicative capacity in addition to endothelial cell-related pathways [53].
The delicate balance of ASCs towards an osteogenic or an adipogenic commitment is
well known [54]. In general, osteogenesis and adipogenesis are mutually exclusive or in in-
verse relationships. For the average of the three donors, we found a significantly increased
PPAR-γ-2 expression (Figure 2J), a central marker during adipogenesis. The same was
found for a 2-week experiment a normal osteogenic induction medium (Figure A1,B) [30].
In contrast, ALP expression (early osteogenic marker) was significantly downregulated at 1
week in the presence of 5 µg/mL aCaP, while Runx2 (a key regulator for osteogenesis [55])
was downregulated for 5, but upregulated for 50 µg/mL aCaP during the same time period.
However, a look at individual responses towards aCaP exposition revealed that 2/3 donors
showed an individual downregulation of PPAR-γ-2 at 1 week (5 µg/mL compared to no
aCaP) and only one out of three donors a significant upregulation at 1 week (50 µg/mL
compared to 5 µg/mL aCaP).
As for ALP, individual consideration of the gene expression dynamics revealed a
downregulation in 1/3 during the first seven days, followed by a significant upregulation
in the following seven days by 2/3 of the donors (50 µg/mL compared to 5 µg/mL aCaP),
going along with the determined upregulation of ALP under normal osteogenic culture
medium conditions (Figure 1A,B). The commitment of ASCs exposed to conventional
osteogenic induction medium at two weeks with a simultaneous upregulation of PPAR-γ-2
and ALP (both around 3-fold), which is similar to our aCaP results, may again reflect
different subpopulations in the ASCs of the three donors; with different amounts of “osteo-
prone” and “adipo-prone” cells [28].
It seems that the sensitive balance favoring either adipo- or osteogenesis with its
reported key factor Msx2, regulating this switch, and its downstream transcription factor
Runx2 might be dependent on the specific composition of the subpopulations given in the
isolated ASCs [39]. Otherwise, the individual dynamics would not differ to such an extent
as found here. It has been shown before that ASCs from each individual donor may vary
quite a lot with respect to multilineage differentiation capacity, although they were isolated
by the same protocol [56].
Besides the individual response of the three donors towards the aCaP suspension,
the complex kinetics of aCaP transformation to HAp [8], all thermodynamic equilibria
of calcium phosphate phases with dissolution and precipitation [7,12,57] also have to be
accounted for the response of the (heterogeneous) ASCs to aCaP nanoparticle exposition.
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In this regard, some worthwhile considerations about the calcium phosphate phases
must be made that could be present in our experimental system besides the initially
suspended aCaP nanoparticles. The free Ca2+ and the Pi ion concentrations were assessed
in the culture media (Figure 3). Although our DMEM basal culture medium should have
had a total calcium ion concentration of 1.8 mM, we measured around 2.3 mM in all samples
where no aCaP was suspended (control). Obviously, a higher basal Ca2+ concentration was
present. For the samples with additional aCaP nanoparticles, an increase in Ca2+ on top of
the basal concentration was measured that peaked at day 7 and decreased a bit on day 14.
On the other hand, Pi concentrations were overall lower than theoretically given by the
DMEM medium (0.9 mM); they were around 0.6 mM without further aCaP addition, as
well as roughly 0.7 mM (at 5 µg/mL aCaP) and 0.8 mM (at 50 µg/mL aCaP), respectively.
Based on those concentrations, we calculated the reaction coefficient Qs0 (ionic activity
product based on actual concentrations, no correction for ionic strength) and compared
them with solubility constants (Ks0) reported and determined at 37
◦C for a set of different
calcium phosphate phases [32] (Table 4). First, we considered hydroxyapatite (HAp)
formation because the transformation of aCaP into HAp is a well-known reaction [8],
and found that all our systems were oversaturated with regard to HAp (for all systems
logQs0-logKs0 > 70). Obviously, the calcium and phosphate concentrations were metastable
with respect to HAp precipitation.
The examination of further phases revealed that the systems were also oversatu-
rated with respect to octocalciumphophate, but undersaturated with respect to mono-
calciumphosphate monohydrate (for all systems logQs0-logKs0 < −7). From the actual
concentrations of the calcium ions and a comparison to their theoretical concentration
under the assumption that all aCaP nanoparticles would have been dissolved, it was con-
cluded that some of the aCaP had dissolved, but not all; because actual concentrations were
still lower at 50 µg/mL aCaP where a theoretical [Ca2+] increase of 26.8% was maximally
expected (from 2.3 mM (baseline here) to approximately 2.9 mM (if all aCaP had dissolved)),
with a measured increase to around 2.5 mM only. Moreover, the saturation status with
respect to further calcium phosphate phases is summarized in Table 4. Our systems were
oversaturated with respect to α-TCP, β-TCP, CDHAp, tetracalciumphosphate, besides the
already mentioned HAp and octacalciumphosphate. For two of the considered calcium
phosphate phases, the saturation status was near equilibrium, for dicalciumphosphate
dehydrate (brushite) and dicalciumphosphate anhydrate (monetite), respectively. Overall,
the chemical composition for all conditions tested here remained approximately constant
over time.
Having this chemical composition in mind, with only small changes in calcium and
phosphate ion concentrations because of aCaP nanoparticle suspension, the high impact
on the gene expression of human ASCs gains particular attention. It has to be stressed that
without changing the saturation status of the culture medium much, aCaP nanoparticles
impact ASC gene expression quite impressively. Therefore, we mainly conclude that there
is a high sensitivity of human ASCs towards aCaP nanoparticles suspended in the culture
medium at very low concentrations, such as 5 or 50 µg/mL. Although free ion concentra-
tions did not vary to a great extent, the cells sensed the suspended aCaP nanoparticles and
possibly their transformation products, such as HAp, either by adherence of the particles
on their cell surfaces or also by incorporation of those nanoparticles. Like this, aCaP
nanoparticles might be used in the future as a suitable phosphate source in such small
concentrations as applied here. Further, they could be used to trigger a desired osteogenic
and angiogenic commitment in mesenchymal stem cells—particularly in combination with
biomaterials for bone tissue engineering.
Limitations
As we addressed only short term commitment of human ASCs within a time frame
of two weeks, the study is limited to this period. Longer experiments aiming to study
full differentiation, not just changes in commitment, might be interesting and widen the
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perspective. A further limitation of the study is that we do not know how fast aCaP
nanoparticles suspended in DMEM transform to HAp and how fast they dissolve. Fur-
thermore, we cannot give information about agglomerations of aCaP nanoparticles in the
culture medium, which might also affect the commitment of the stem cells.
5. Conclusions
The addition of aCaP nanoparticles to the basal culture medium as a suspension
enhanced CD73, CD31, and CD34 gene expression of human ASCs, averaged over three
donors. Osteogenic marker genes, such as ALP or Runx2, experienced a downregulation.
However, individual responses revealed a high inter-donor variability, with ALP and
Runx2 enhancements for distinct conditions: Two out of three donors exhibited a significant
upregulation at day 14 and 50 µg/mL aCaP compared to 5 µg/mL aCaP.
Free calcium and phosphate ion concentrations showed an oversaturated status with
respect to several calcium phosphate phases, among them hydroxyapatite. This metastable
status, however, did not change much over the period of two weeks and for the con-
centrations of 5 or 50 µg/mL aCaP, respectively. We conclude that not only the free ion
concentration changes affect the gene expression, but also the direct interaction of the
suspended particles, either by cell surface adherence or by incorporation. Like this, the
suspension of low concentrations of aCaP nanoparticles in normal culture medium DMEM
may be used to tune stem cells towards an angiogenic/osteogenic commitment, which
might be interesting in future bone tissue engineering approaches.
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Appendix A
Besides gene expression analysis after aCaP nanoparticle exposure, we have also
performed a 2-week experiment where ASCs were exposed to an osteogenic induction
medium. Gene expression of the same markers as determined in the aCaP nanoparticle










Figure A1. Average manifold induction of different genes. Experiments were carried out with
osteogenic induction culture medium (see Section 2 for supplements) and 14 days in culture. Markers
for stem cells, such as CD73, CD90 and CD105; and endothelial cells, such as CD31 and CD34,
respectively (A) and markers for osteogenesis (ALP, Runx2, Collagen I and OC = osteocalcin),
adipogenesis (PPAR-γ-2) and chondrogenesis (Sox9) (B) are shown. Results are given as means, and
error bars denote standard deviations. Key: p < 0.05 (*); p < 0.01 (**) and p < 0.001 (***).
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